Progresif Miyoklonik Epilepsi
Özet
Progresif miyoklonik epilepsiler, miyoklonus, nöbetler ve progresif nörolojik bozulma ile karakterize, klinik ve genetik olarak heterojen bir hastalık grubudur. Tanı süreci semptomların diğer hastalıklarla benzerliği nedeniyle zordur ve genellikle genetik analizlere dayanır. Hastalıkların çoğu otozomal resesif kalıtım gösterse de dominant ve mitokondriyal geçişli tipleri de mevcuttur. Tedavi yaklaşımı büyük oranda semptomatik ve destekleyici olup, bazı alt tipler için spesifik genetik veya enzimatik tedavi yöntemleri üzerinde çalışmalar sürmektedir.
Progressive myoclonic epilepsies constitute a clinically and genetically heterogeneous group of diseases characterized by myoclonus, epileptic seizures, and progressive neurological deterioration. Diagnosis is challenging due to the clinical overlap with other neurodegenerative and epileptic conditions, typically necessitating comprehensive genetic analysis. While most conditions in this group follow an autosomal recessive inheritance pattern, dominant and mitochondrial forms also occur. Treatment approaches are predominantly symptomatic and supportive, although research into specific genetic and enzymatic therapies for certain subtypes is ongoing.
Referanslar
Kälviäinen R. Progressive Myoclonus Epilepsies. Semin Neurol. 2015 Jun;35(3):293–9.
Tatlı B. Çocukluk Çağı Epileptik Spazm ve Miyokloniler. Kumandaş S, Canpolat M, editörler. Çocukluk Çağı Epilepsileri.1. Baskı. Ankara: Türkiye Klinikleri; 2020. Sep 22; p117-119
Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group. Ann Neurol. 1990 Jul;28(1):113–6.
Arora V, Verma I. Aicardi’s Diseases of the Nervous System in Childhood: Alexis Arzimanoglou, University Hospitals of Lyon, France with Anne O’Hare, Michael V Johnston, Robert Ouvrier (eds). Indian J Pediatr. 2019 Oct 1;86(10):972–972.
Apak S, Tatlı B. Pediatrik Epiloptoloji. 2019;2.
Ibrahim F, Murr N. Lafora Disease. StatPearls Publishing; 2020 [cited 2021 Jun 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482229/
Minassian BA, Ianzano L, Meloche M, Andermann E, Rouleau GA, Delgado-Escueta AV, et al. Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology. 2000 Aug 8;55(3):341–6.
Ramachandran N, Girard J-M, Turnbull J, Minassian BA. The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia. 2009;50(s5):29–36.
Duran J, Gruart A, García-Rocha M, Delgado-García JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Human Molecular Genetics. 2014 Jun 15;23(12):3147–56.
Andrade DM, Ackerley CA, Minett TSC, Teive H a. G, Bohlega S, Scherer SW, et al. Skin biopsy in Lafora disease: Genotype–phenotype correlations and diagnostic pitfalls. Neurology. 2003 Dec 9;61(11):1611–4.
Mikati MA, Tabbara F. Managing Lafora body disease with vagal nerve stimulation. Epileptic Disord. 2017 Mar 1;19(1):82–6.
Orphanet: Unverricht Lundborg disease [Internet]. [cited 2021 Jun 13]. Available from: https://www.orpha.net/consor/cgi-bin/OC
Crespel A, Ferlazzo E, Franceschetti S, Genton P, Gouider R, Kälviäinen R, et al. Unverricht-Lundborg disease. Epileptic Disorders. 2016 Sep 1;18(2):28–37.
Haan G-JD, Halley DJJ, Doelman JC, Geesink HH, Augustijn PB, Jager-Jongkind AD, et al. Univerricht-Lundborg Disease: Underdiagnosed in the Netherlands. Epilepsia. 2004;45(9):1061–3.
Koskiniemi M, Toivakka E, Donner M. Progressive myoclonus epilepsy. Acta Neurologica Scandinavica. 2009 Jun 1;50:333–59.
Crest C, Dupont S, Leguern E, Adam C, Baulac M. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004 Feb 24;62(4):640–3.
Remes AM, Majamaa-Voltti K, Kärppä M, Moilanen JS, Uimonen S, Helander H, et al. Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population. Neurology. 2005 Mar 22;64(6):976–81.
Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW, et al. Prevalence of mitochondrial DNA disease in adults. Annals of Neurology. 2008;63(1):35–9.
Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001 Mar;49(3):377–83.
Hameed S, Tadi P. Myoclonic Epilepsy and Ragged Red Fibers. [Updated 2021 Feb 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan 7.
Lamperti C, Zeviani M. Myoclonus epilepsy in mitochondrial disorders. Epileptic Disord. 2016 Sep 1;18(S2):94–102.
Shoffner JM, Wallace DC. Mitochondrial genetics: principles and practice. Am J Hum Genet [Internet]. 1992 Dec;51(6):1179–86.
Lorenzoni PJ, Scola RH, Kay CSK, Silvado CES, Werneck LC. When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? Arq Neuropsiquiatr. 2014 Oct;72(10):803–11.
Finsterer J, Zarrouk-Mahjoub S. Management of epilepsy in MERRF syndrome. Seizure. 2017 Aug 1;50:166–70.
Velez-Bartolomei F, Lee C, Enns G. Myoclonic Epilepsy Associated with Ragged Red Fibers. GeneReviews, University of Washington, Seattle; 2018 Nov 29
Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol. 2003 Jan;62(1):1–13.
Jadav RH, Sinha S, Yasha TC, Aravinda H, Gayathri N, Rao S, et al. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014 Jan;50(1):85–95.
Pérez-Poyato MS, Marfa MP, Abizanda IF, Rodriguez-Revenga L, Sánchez VC, González MJM, et al. Late infantile neuronal ceroid lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients. J Child Neurol. 2013 Apr;28(4):470–8.
Ranta S, Topcu M, Tegelberg S, Tan H, Ustübütün A, Saatci I, et al. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat. 2004 Apr;23(4):300–5.
Santavuori P, Lauronen L, Kirveskari K, Aberg L, Sainio K. Neuronal ceroid lipofuscinoses in childhood. Suppl Clin Neurophysiol. 2000;53:443–51.
Markham A. Cerliponase Alfa: First Global Approval. Drugs. 2017 Jul;77(11):1247–9.
Tsuji S. Dentatorubral-pallidoluysian atrophy. Handb Clin Neurol. 2012;103:587–94.
Rocha Cabrero F, De Jesus O. Dentatorubral Pallidoluysian Atrophy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
Carroll LS, Massey TH, Wardle M, Peall KJ. Dentatorubral-pallidoluysian Atrophy: An Update. Tremor Other Hyperkinet Mov (N Y). 2018;8:577.
Sugiyama A, Sato N, Nakata Y, Kimura Y, Enokizono M, Maekawa T, et al. Clinical and magnetic resonance imaging features of elderly onset dentatorubral-pallidoluysian atrophy. J Neurol. 2018 Feb;265(2):322–9.
Franceschetti S, Canafoglia L. Sialidoses. Epileptic Disorders. 2016;18(s2):S89–93.
